Skip to main content
. 2023 Dec 23;25(1):232. doi: 10.3390/ijms25010232

Figure 9.

Figure 9

Proposed model illustrating the effects of CUR and RES combined treatment on tumor cells and PBMCs. The combination of bioavailable concentrations of CUR and RES reduced cancer cell survival without affecting PBMC viability, but instead increasing T cell activation (CD25+) and recognition of tumor by NK cells through the concomitant upregulation of the activating receptors (NKG2D and NKp30) and downregulation of the inhibitory and exhaustion receptors (KIR2DL2/L3/S2, KIR3DL1 and TIGIT). This figure was created using BioRender.com (accessed on 11 December 2023).